论文部分内容阅读
益赛普(国产注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白)适用于中至重度活动性类风湿关节炎患者,鉴于该药副作用及不良反应,应用于高龄患者仍需谨慎。我科2013年3月~2016年3月收治的16例高龄活动性类风湿关节炎患者,由于传统慢作用抗风湿药治疗效果差或因合并多脏器疾病无法耐受其副作用,而选用益赛普进行治疗,本文回顾分析临床治疗效果及不良反应,报告如下。1资料与方法
Yisip (domestic injection of recombinant human type Ⅱ tumor necrosis factor receptor - antibody fusion protein) for moderate to severe active rheumatoid arthritis patients, in view of the drug side effects and adverse reactions, applied to elderly patients still need to be cautious. 16 cases of active rheumatoid arthritis patients admitted to our department from March 2013 to March 2016 were selected for their benefits due to the poor efficacy of traditional slow acting antirheumatic drugs or their inability to tolerate multiple organ diseases Saipu for treatment, the paper reviewed the clinical effects and adverse reactions, the report is as follows. 1 data and methods